These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31115879)

  • 21. Inhibitory 2B4 contributes to NK cell education and immunological derangements in XLP1 patients.
    Meazza R; Falco M; Marcenaro S; Loiacono F; Canevali P; Bellora F; Tuberosa C; Locatelli F; Micalizzi C; Moretta A; Mingari MC; Moretta L; Aricò M; Bottino C; Pende D
    Eur J Immunol; 2017 Jun; 47(6):1051-1061. PubMed ID: 28386908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of natural killer cell functions by interactions between 2B4 and CD48 in cis and in trans.
    Claus M; Wingert S; Watzl C
    Open Biol; 2016 May; 6(5):. PubMed ID: 27249817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments.
    Chu E; Wu J; Kang SS; Kang Y
    Curr Oncol; 2023 Aug; 30(9):7891-7903. PubMed ID: 37754488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Signaling Lymphocytic Activation Molecule Family Receptor Homologs in New World Monkey Cytomegaloviruses.
    Pérez-Carmona N; Farré D; Martínez-Vicente P; Terhorst C; Engel P; Angulo A
    J Virol; 2015 Nov; 89(22):11323-36. PubMed ID: 26339044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective elimination of immunosuppressive T cells in patients with multiple myeloma.
    Awwad MHS; Mahmoud A; Bruns H; Echchannaoui H; Kriegsmann K; Lutz R; Raab MS; Bertsch U; Munder M; Jauch A; Weisel K; Maier B; Weinhold N; Salwender HJ; Eckstein V; Hänel M; Fenk R; Dürig J; Brors B; Benner A; Müller-Tidow C; Goldschmidt H; Hundemer M
    Leukemia; 2021 Sep; 35(9):2602-2615. PubMed ID: 33597728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
    Hsi ED; Steinle R; Balasa B; Szmania S; Draksharapu A; Shum BP; Huseni M; Powers D; Nanisetti A; Zhang Y; Rice AG; van Abbema A; Wong M; Liu G; Zhan F; Dillon M; Chen S; Rhodes S; Fuh F; Tsurushita N; Kumar S; Vexler V; Shaughnessy JD; Barlogie B; van Rhee F; Hussein M; Afar DE; Williams MB
    Clin Cancer Res; 2008 May; 14(9):2775-84. PubMed ID: 18451245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Editorial: Immunotherapy in Multiple Myeloma.
    Giuliani N; Malavasi F
    Front Immunol; 2019; 10():1945. PubMed ID: 31475006
    [No Abstract]   [Full Text] [Related]  

  • 28. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
    Palumbo A; Sonneveld P
    Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD48 as a novel molecular target for antibody therapy in multiple myeloma.
    Hosen N; Ichihara H; Mugitani A; Aoyama Y; Fukuda Y; Kishida S; Matsuoka Y; Nakajima H; Kawakami M; Yamagami T; Fuji S; Tamaki H; Nakao T; Nishida S; Tsuboi A; Iida S; Hino M; Oka Y; Oji Y; Sugiyama H
    Br J Haematol; 2012 Jan; 156(2):213-24. PubMed ID: 22098460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of SLAM (CD150) cell-surface receptors on human B-cell subsets: from pro-B to plasma cells.
    De Salort J; Sintes J; Llinàs L; Matesanz-Isabel J; Engel P
    Immunol Lett; 2011 Jan; 134(2):129-36. PubMed ID: 20933013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monoclonal antibody therapy in multiple myeloma.
    Touzeau C; Moreau P; Dumontet C
    Leukemia; 2017 May; 31(5):1039-1047. PubMed ID: 28210004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Signaling Lymphocytic Activation Molecule Family Member 7 Engagement Restores Defective Effector CD8+ T Cell Function in Systemic Lupus Erythematosus.
    Comte D; Karampetsou MP; Yoshida N; Kis-Toth K; Kyttaris VC; Tsokos GC
    Arthritis Rheumatol; 2017 May; 69(5):1035-1044. PubMed ID: 28076903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody treatment in multiple myeloma.
    Maples KT; Johnson C; Lonial S
    Clin Adv Hematol Oncol; 2021 Mar; 19(3):166-174. PubMed ID: 33739965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel targets for the treatment of relapsing multiple myeloma.
    Giuliani N; Accardi F; Marchica V; Dalla Palma B; Storti P; Toscani D; Vicario E; Malavasi F
    Expert Rev Hematol; 2019 Jul; 12(7):481-496. PubMed ID: 31125526
    [No Abstract]   [Full Text] [Related]  

  • 35. Current antibody-based therapies for the treatment of multiple myeloma.
    Varga C; Waldschmidt JM; Gandolfi S; Richardson PG
    Clin Adv Hematol Oncol; 2020 Nov; 18(11):736-748. PubMed ID: 33406065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells.
    Kiel MJ; Yilmaz OH; Iwashita T; Yilmaz OH; Terhorst C; Morrison SJ
    Cell; 2005 Jul; 121(7):1109-21. PubMed ID: 15989959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7.
    Kikuchi J; Hori M; Iha H; Toyama-Sorimachi N; Hagiwara S; Kuroda Y; Koyama D; Izumi T; Yasui H; Suzuki A; Furukawa Y
    Leukemia; 2020 Jan; 34(1):180-195. PubMed ID: 31358854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic antibodies for multiple myeloma.
    Ishida T
    Jpn J Clin Oncol; 2018 Nov; 48(11):957-963. PubMed ID: 30329116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The murine NK receptor 2B4 (CD244) exhibits inhibitory function independent of signaling lymphocytic activation molecule-associated protein expression.
    Mooney JM; Klem J; Wülfing C; Mijares LA; Schwartzberg PL; Bennett M; Schatzle JD
    J Immunol; 2004 Sep; 173(6):3953-61. PubMed ID: 15356144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 2B4 and CD48: A powerful couple of the immune system.
    Pahima H; Puzzovio PG; Levi-Schaffer F
    Clin Immunol; 2019 Jul; 204():64-68. PubMed ID: 30366105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.